|
Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results revealed that the expression of CtBP2, but not CtBP1, was upregulated in OS tissue samples and the elevated expression level of CtBP2 was notably associated with distant metastasis.
|
31214864 |
2019 |
|
Sensory denervation disorder
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Using a combination of histological and functional approaches, we demonstrated four key findings: (1) selective synaptic deafferentation is sufficient to generate acute vestibular syndrome with characteristics similar to those reported in patients; (2) the reduction of the vestibulo-ocular reflex and posturo-locomotor deficits mainly depends on spared synapses; (3) damaged primary vestibular synapses can be repaired over the days and weeks following deafferentation; and (4) the synaptic repair process occurs through the re-expression and re-pairing of synaptic proteins such as CtBP2 and SHANK-1.
|
31213478 |
2019 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
These results indicated that Brn4 promoted the neuronal differentiation of NSCs via inhibition of CtBP2 and is a potential tool for generating neurons in cell replacement therapy of neurodegenerative diseases and brain injury.
|
31518606 |
2019 |
|
Osteosarcoma of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results revealed that the expression of CtBP2, but not CtBP1, was upregulated in OS tissue samples and the elevated expression level of CtBP2 was notably associated with distant metastasis.
|
31214864 |
2019 |
|
Childhood Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results revealed that the expression of CtBP2, but not CtBP1, was upregulated in OS tissue samples and the elevated expression level of CtBP2 was notably associated with distant metastasis.
|
31214864 |
2019 |
|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
As CtBP2 is targetable by an inhibitor of its dehydrogenase domain, understanding CtBP2's role in adenoma formation is necessary to optimize CtBP-targeted therapies in <i>Apc</i> mutated human neoplasia.
|
30197752 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that CtBP2 plays a crucial role in NSCLC progression and CDDP sensitivity, and that CtBP2 depletion can provide a new target for NSCLC treatment.
|
30334447 |
2018 |
|
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
C-terminal binding protein‑2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis.
|
29658564 |
2018 |
|
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
C-terminal binding protein‑2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis.
|
29658564 |
2018 |
|
Malignant neoplasm of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
C-terminal binding protein‑2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis.
|
29658564 |
2018 |
|
Intestinal Polyposis
|
0.010 |
Biomarker
|
disease |
BEFREE |
C-terminal binding protein 2 (CtBP2) drives intestinal polyposis in the <i>Apc</i><sup>
|
30197752 |
2018 |
|
Multiple Chronic Conditions
|
0.010 |
Biomarker
|
disease |
BEFREE |
We postulate that RIBEYE disruption is partially compensated by multi-AZ organization.
|
29328020 |
2018 |
|
Anorexia Nervosa
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, all AN susceptibility alleles were consistently associated with increased BMI.None of the genes (chr.10: CTBP2, chr.19: CCNE1, chr.
|
27184124 |
2017 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MiR-338 suppresses cell proliferation and invasion by targeting CTBP2 in glioma.
|
28826173 |
2017 |
|
Lupus Vulgaris
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, the ZEB1-CtBP2 complex on negative regulatory element A was significantly upregulated after PMA/ionomycin stimulation in lupus CD4<sup>+</sup> T cells.
|
28438897 |
2017 |
|
Lupus Erythematosus, Discoid
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, the ZEB1-CtBP2 complex on negative regulatory element A was significantly upregulated after PMA/ionomycin stimulation in lupus CD4<sup>+</sup> T cells.
|
28438897 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, we hypothesized that decreased miR-200a-3p causes IL-2 deficit through the ZEB1-CtBP2 and/or ZEB2-CtBP2 complex in SLE CD4<sup>+</sup> T cells.
|
28438897 |
2017 |
|
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, CtBP2 is overexpressed in GC and may accelerate GC tumorigenesis and metastasis, which could represent an independent prognostic marker and promising therapeutic target for GC.
|
28404932 |
2017 |
|
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that CtBP2 may be a potential target to suppress tumorigenesis in neuroblastoma.
|
28179207 |
2017 |
|
polyps
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Ctbp2 heterozygosity increased the median survival of Apc<sup>min/+</sup> mice from 21 to 48 weeks, and reduced polyp formation by 90%, with Ctbp2<sup>+/-</sup> polyps exhibiting reduced levels of β-catenin and its oncogenic transcriptional target, cyclin D1.
|
28414304 |
2017 |
|
Respiration Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
CXCL6, CXCL8, KIT and CTBP2 were highlighted as candidate genes that might play important roles in determining resistance/susceptibility to swine EP-like respiratory disease.
|
27615547 |
2017 |
|
Respiratory Tract Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
CXCL6, CXCL8, KIT and CTBP2 were highlighted as candidate genes that might play important roles in determining resistance/susceptibility to swine EP-like respiratory disease.
|
27615547 |
2017 |
|
Lupus Erythematosus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, the ZEB1-CtBP2 complex on negative regulatory element A was significantly upregulated after PMA/ionomycin stimulation in lupus CD4<sup>+</sup> T cells.
|
28438897 |
2017 |
|
Stomach Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, CtBP2 is overexpressed in GC and may accelerate GC tumorigenesis and metastasis, which could represent an independent prognostic marker and promising therapeutic target for GC.
|
28404932 |
2017 |
|
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that CtBP2 may be a potential target to suppress tumorigenesis in neuroblastoma.
|
28179207 |
2017 |